IDEAYA Biosciences, Inc. Stock price

Equities

IDYA

US45166A1025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
43.88 USD +1.32% Intraday chart for IDEAYA Biosciences, Inc. -3.84% +23.33%
Sales 2024 * 19.11M Sales 2025 * 97.66M Capitalization 3.27B
Net income 2024 * -165M Net income 2025 * -126M EV / Sales 2024 * 139 x
Net cash position 2024 * 620M Net cash position 2025 * 516M EV / Sales 2025 * 28.2 x
P/E ratio 2024 *
-19.8 x
P/E ratio 2025 *
-25.9 x
Employees 124
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.02%
More Fundamentals * Assessed data
Dynamic Chart
Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating MT
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients MT
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer CI
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target MT
Transcript : IDEAYA Biosciences, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 08:00 AM
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating MT
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines MT
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Posts Q4 Revenue $3.9M MT
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Ideaya Biosciences Insider Sold Shares Worth $4,495,550, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on IDEAYA Biosciences to $53 From $36, Maintains Buy Rating MT
Wedbush Raises Price Target on IDEAYA Biosciences to $46 From $43, Maintains Outperform Rating MT
RBC Adjusts IDEAYA Biosciences' Price Target to $43 From $36, Keeps Outperform Rating MT
More news
1 day+1.32%
1 week-3.84%
Current month-1.83%
1 month-1.55%
3 months+22.47%
6 months+65.02%
Current year+23.33%
More quotes
1 week
42.13
Extreme 42.13
44.17
1 month
42.13
Extreme 42.13
47.72
Current year
33.46
Extreme 33.46
47.74
1 year
13.29
Extreme 13.29
47.74
3 years
8.14
Extreme 8.14
47.74
5 years
2.95
Extreme 2.95
47.74
10 years
2.95
Extreme 2.95
47.74
More quotes
Managers TitleAgeSince
Founder 49 15-05-31
Director of Finance/CFO 38 16-07-31
Chief Tech/Sci/R&D Officer - 21-10-31
Members of the board TitleAgeSince
Director/Board Member 64 16-05-05
Director/Board Member 68 19-12-16
Director/Board Member 68 22-04-04
More insiders
Date Price Change Volume
24-03-28 43.88 +1.32% 729,125
24-03-27 43.31 +1.88% 634,562
24-03-26 42.51 +0.47% 695,749
24-03-25 42.31 -1.67% 670,365
24-03-22 43.03 -5.70% 582,968

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
43.88 USD
Average target price
53.27 USD
Spread / Average Target
+21.41%
Consensus
  1. Stock
  2. Equities
  3. Stock IDEAYA Biosciences, Inc. - Nasdaq